Netherlands-based investment group Gilde Healthcare has finally closed its new Venture & Growth VI fund with committed funding of €740 million, well ahead of its origi
Netherlands-based investment group Gilde Healthcare has raised €600 million ($658 million) for a new transatlantic fund intended to support innovative ventures in digital
Astellas has added another gene therapy to its pipeline, taking an option on a clinical-stage candidate for a rare genetic form of dementia from UK biotech AviadoBio for around $50 million.